{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:33:27Z","timestamp":1793723607392,"version":"4.6.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ekir.2023.08.003","type":"journal-article","created":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T12:03:40Z","timestamp":1691928220000},"page":"2243-2253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia"],"prefix":"10.1016","volume":"8","author":[{"given":"Kosaku","family":"Nitta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Itoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Ikejiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2023.08.003_bib1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.08.003_bib2","doi-asserted-by":"crossref","unstructured":"N. Kimata, J.M. Albert, T. Akiba, et al., Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study, Hemodial Int, 11, 2007, 340\u2013348, doi: 10.1111\/j.1542-4758.2007.00190.x.","DOI":"10.1111\/j.1542-4758.2007.00190.x"},{"key":"10.1016\/j.ekir.2023.08.003_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2015.01.009","article-title":"Hyperphosphatemia management in patients with chronic kidney disease","volume":"24","author":"Shaman","year":"2016","journal-title":"Saudi Pharm J"},{"issue":"suppl 3","key":"10.1016\/j.ekir.2023.08.003_bib4","doi-asserted-by":"crossref","first-page":"iii28","DOI":"10.1093\/ndt\/gfy174","article-title":"Cardiovascular disease in dialysis patients","volume":"33","author":"Cozzolino","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.08.003_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.08.003_bib6","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.08.003_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4009\/jsdt.45.301","article-title":"The Japanese Society for Dialysis Therapy. Clinical practice guideline for CKD-MBD","volume":"45","year":"2012","journal-title":"Nihon Toseki Igakkai Zasshi"},{"issue":"suppl 3","key":"10.1016\/j.ekir.2023.08.003_bib8","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.08.003_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1681\/ASN.2020050598","article-title":"Optimal phosphate control related to coronary artery calcification in dialysis patients","volume":"32","author":"Isaka","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.08.003_bib10","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ekir.2019.06.002","article-title":"Strategies for phosphate control in patients with CKD","volume":"4","author":"Barreto","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.08.003_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","article-title":"Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS","volume":"20","author":"Fissell","year":"2016","journal-title":"Hemodial Int"},{"key":"10.1016\/j.ekir.2023.08.003_bib12","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/ndt\/gft280","article-title":"Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis","volume":"29","author":"Wang","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.08.003_bib13","first-page":"673","article-title":"Adherence to phosphate binders in hemodialysis patients: prevalence and determinants","volume":"27","author":"Van Camp","year":"2014","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2023.08.003_bib14","doi-asserted-by":"crossref","first-page":"227ra36","DOI":"10.1126\/scitranslmed.3007790","article-title":"Intestinal inhibition of the Na+\/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans","volume":"6","author":"Spencer","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ekir.2023.08.003_bib15","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1681\/ASN.2014030317","article-title":"Gastrointestinal inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD","volume":"26","author":"Labont\u00e9","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.08.003_bib16","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1681\/ASN.2020101398","article-title":"A\u00a0randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY)","volume":"32","author":"Pergola","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.08.003_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1159\/000516156","article-title":"Therapeutic effects of add-on tenapanor for hemodialysis patients with refractory hyperphosphatemia","volume":"52","author":"Shigematsu","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2023.08.003_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ekir.2021.11.008","article-title":"Dose-response of tenapanor in patients with hyperphosphatemia undergoing hemodialysis in Japan-a phase 2 randomized trial","volume":"7","author":"Inaba","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.08.003_bib19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1681\/ASN.2018080832","article-title":"Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial","volume":"30","author":"Block","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.08.003_bib20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.ajkd.2023.03.019","article-title":"Tenapanor for the treatment of hyperphosphatemia in Japanese hemodialysis patients: a randomized phase 3 monotherapy study with an \u201cUP-titration\u201d regimen","volume":"82","author":"Fukagawa","year":"2023","journal-title":"Am J Kidney\u00a0Dis"},{"key":"10.1016\/j.ekir.2023.08.003_bib21","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/j.1572-0241.2007.01321.x","article-title":"Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis","volume":"102","author":"Cano","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ekir.2023.08.003_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s41100-019-0246-3","article-title":"Constipation in chronic kidney disease: it is time to reconsider","volume":"5","author":"Ikee","year":"2019","journal-title":"Ren Replace Ther"},{"key":"10.1016\/j.ekir.2023.08.003_bib23","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1172\/JCI36479","article-title":"Endocrine functions of bone in mineral metabolism regulation","volume":"118","author":"Quarles","year":"2008","journal-title":"J\u00a0Clin Invest"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923014201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923014201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:48:09Z","timestamp":1778892489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024923014201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2468024923014201"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2023.08.003","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.10.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}